ArriVent BioPharma, Inc.
Description
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
About
CEO
Dr. Zhengbin Yao Ph.D.
Employees
40
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNMS
Address
18 Campus Boulevard, Newtown Square, PA 19073, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 14, 2024 | -1.00 | -0.61 | 0.39 | -39.00% |
| Aug 15, 2024 | -0.64 | -0.65 | -0.01 | 1.56% |
| Jan 26, 2024 | -1.10 | -0.70 | 0.40 | -36.36% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 2 | — | 4 |
| Average estimate | — | -0.79 | — | -3.49 |
| Low estimate | — | -0.80 | — | -3.80 |
| High estimate | — | -0.78 | — | -3.34 |
| Last year EPS | — | -0.70 | — | -2.69 |
[stock_revenue_estimate]
Growth estimates
Current qtr
97.460%
Next qtr. (Mar 2025)
-12.860%
Current year
91.680%
Next year (Dec 2025)
-29.770%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | |
|---|---|
| Fiscal date | 2023-12-31 |
| Total reported revenue | — |
| Cost of revenue | — |
| Gross profit | — |
| Operating expense | |
| Research & development | 64.88M |
| Selling general and admin | 9.71M |
| Other operating expenses | — |
| Operating income | -74.59M |
| Non operating interest income | |
| Income | 5.26M |
| Expense | — |
| Other income expense | — |
| Pretax income | -69.33M |
| Tax provision | — |
| Net income | -69.33M |
| Basic EPS | -2.17 |
| Diluted EPS | -2.17 |
| Basic average shares | 31.96M |
| Diluted average shares | 31.96M |
| EBITDA | -74.59M |
| Net income from continuing op. | -69.33M |
| Minority interests | — |
| Preferred stock dividends | — |
Balance sheet
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 163.10M | 182.83M | 43.04M |
| Current assets | |||
| Cash | — | 163.37M | 37.28M |
| Cash equivalents | — | — | — |
| Cash and cash equivalents | 150.39M | 163.37M | 37.28M |
| Other short term investments | — | — | — |
| Accounts receivable | — | — | — |
| Other receivables | 240,000 | 177,000 | 29,000 |
| Inventory | — | — | — |
| Prepaid assets | 8.82M | 18.75M | 5.42M |
| Restricted cash | — | — | — |
| Assets held for sale | — | — | — |
| Hedging assets | — | — | — |
| Other current assets | 8.58M | 18.57M | 5.39M |
| Non current assets | |||
| Properties | — | — | — |
| Land and improvements | — | — | — |
| Machinery furniture equipment | — | — | — |
| Construction in progress | — | — | — |
| Leases | — | — | — |
| Accumulated depreciation | — | — | — |
| Goodwill | — | — | — |
| Investment properties | — | — | — |
| Financial assets | — | — | — |
| Intangible assets | — | — | — |
| Investments and advances | — | — | — |
| Other non current assets | 2.84M | 72,000 | 87,000 |
| Total liabilities | 316.29M | 267.94M | 1.82M |
| Current liabilities | |||
| Accounts payable | 4.53M | 3.09M | 293,000 |
| Accrued expenses | 3.60M | 2.46M | 612,000 |
| Short term debt | 140,000 | 128,000 | — |
| Deferred revenue | — | — | — |
| Tax payable | — | — | — |
| Pensions | 3.35M | 2.68M | 913,000 |
| Other current liabilities | — | — | — |
| Non current liabilities | |||
| Long term debt | 177,000 | 11,000 | — |
| Provision for risks and charges | — | — | — |
| Deferred liabilities | — | — | — |
| Derivative product liabilities | — | — | — |
| Other non current liabilities | — | — | — |
| Shareholders equity | |||
| Common stock | — | — | — |
| Retained earnings | -157.85M | -88.51M | -51.61M |
| Other shareholders equity | — | — | — |
| Total shareholders equity | -153.19M | -85.11M | 41.22M |
| Additional paid in capital | 4.65M | 3.40M | 2.96M |
| Treasury stock | — | — | — |
| Minority interest | — | — | — |
Cash flow statement
| 2023 | |
|---|---|
| Operating Activities | |
| Net Income | -69.33M |
| Depreciation | — |
| Deferred Taxes | — |
| Stock-Based Compensation | 895,000 |
| Other Non-Cash Items | — |
| Accounts Receivable | — |
| Accounts Payable | 1.38M |
| Other Assets & Liabilities | -10,000 |
| Operating Cash Flow | -67.07M |
| Investing Activities | |
| Capital Expenditures | — |
| Net Intangibles | — |
| Net Acquisitions | — |
| Purchase of Investments | -25.00M |
| Sale of Investments | 25.00M |
| Investing Cash Flow | — |
| Financing Activities | |
| Long-Term Debt Issuance | — |
| Long-Term Debt Payments | — |
| Other Financing Charges | -2.41M |
| Financing Cash Flow | 42.51M |
| Other Cash Details | |
| End Cash Position | 150.39M |
| Income Tax Paid | — |
| Interest Paid | — |
| Free Cash Flow | -55.84M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Fidelity Select Portfolios - Biotechnology | Nov 30, 2024 | 1,967,500 | 57.55M | 5.84% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 787,080 | 23.02M | 2.34% |
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 784,202 | 22.94M | 2.33% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 335,288 | 9.81M | 1.00% |
| Fidelity Small Cap Index Fund | Oct 31, 2024 | 286,995 | 8.39M | 0.85% |
| iShares Russell 2000 Growth ETF | Nov 30, 2024 | 152,155 | 4.45M | 0.45% |
| Vanguard Russell 2000 Index Fund | Nov 30, 2024 | 132,485 | 3.88M | 0.39% |
| Fidelity Select Portfolios - Pharmaceuticals | Nov 30, 2024 | 128,700 | 3.76M | 0.38% |
| Fidelity Extended Market Index Fund | Nov 30, 2024 | 124,150 | 3.63M | 0.37% |
| Schwab Strategic Tr-Schwab U.S. Small Cap ETF | Nov 30, 2024 | 109,319 | 3.20M | 0.32% |
Article
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers
NEWTOWN SQUARE, Pa. and SHANGHAI, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP) a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it has entered into an exclusive license agreement with Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) for MRG007, an antibody-drug conjugate (ADC) that can target several gastrointestinal (GI) cancers. Under the terms of the agreement, ArriVent obtains the exclusive rights to develop and commercialize MRG007 worldwide outside of Greater China which includes mainland China, Hong Kong, Macau and Taiwan.
Jan 22, 2025
Article
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
Biotech and pharmaceutical companies are well known for raising capital through initial public offerings, or IPOs. Between 2001 and 2023, approximately 24% of IPOs were from biotech and pharmaceutical companies.
Nov 6, 2024
Article
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer
81.8% ORR by BICR and 63.6% confirmed ORR by BICR at the 240 mg dose; 46.2% confirmed ORR in CNS Metastases 90.9% (n = 20/22) of patients with confirmed responses remained on study with a median duration of response not yet reached at time of analysis ArriVent to host virtual webinar on these interim analyses of Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC on September 9, 2024 at 4:30 pm ET NEWTOWN SQUARE, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced positive proof-of-concept randomized global Phase 1b FURTHER interim data for first-line firmonertinib monotherapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR PACC mutations at a Presidential Symposium Presentation at the IASCLC 2024 annual World Conference on Lung Cancer (WCLC), in San Diego, California.
Sep 9, 2024
